首页>投融资

ImmPACT Bio

收并购

ImmPACT Bio USA Inc is a clinical-stage company intended to discover transformative chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's product assures tumor specificity by inducing cytotoxicity only upon engagement of the CAR-T cell with a tumor cell, but not with any normal cell, enabling doctors to differentiate cancerous from noncancerous tissues that affect the treatment thereby mitigating the safety risks associated with current CAR-T technologies..In January 2022, ImmPACT Bio USA Inc had closed $111 million in Series B financing.In August 2020, the company closed US$ 18 million equity financing round, raised US$ 18 million in Series A financing

http://www.futurx.co.il/portfolio/immpact-bio

470194

基本信息

公司全称

ImmPACT Bio USA Inc
类型

T细胞疗法研发商
产业领域

医药研发/制造、化学&生物药
公司人数

15人以下
地址

4010 Adolfo Rd. Camarillo California 39012; US; Telephone: +97289553100; Fax: +97289553111;
联系电话
邮箱

info@immpact-bio.com
成立时间

2017-01-01

投融资

2024-10-31

收并购

未透露

Lyell Immunopharma
2024-02-28

捐赠/众筹/授予

800万美元

California Institute for Regenerative Medicine
2022-01-20

B轮

1.11亿美元

RM Global Partners

奥博资本

VenBio Partners

德诚资本

诺华

Foresite Capital

Surveyor Capital

Bukwang Pharm
2020-08-18

A轮

1800万美元

RM Global Partners

Hayan Health Networks

Johnson & Johnson Development Corporation

奥博资本

Bukwang Pharm

Takeda Ventures

诺华

JVC Investment Partners
加载更多

ImmPACT Bio

基本信息

投融资

相关投融资企业